PROCEPT BioRobotics PRCT
PROCEPT BioRobotics Q1 FY26: revenue $83.1M, up 20%; diluted EPS −$0.56
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001588978-26-000022
Key figures from this report
These are the numbers PROCEPT BioRobotics reported for Q1 FY26, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$83.1M+20% from $69.2M in Q1 FY2510-Q income statement, on EDGAR
- Net income−$31.6MAgainst −$24.7M in Q1 FY2510-Q income statement, on EDGAR
- Diluted EPS−$0.56Against −$0.45 in Q1 FY2510-Q income statement, on EDGAR
- Cash and cash equivalents$245.6M−22% from $316.2M in Q1 FY2510-Q balance sheet, on EDGAR
- Cash from operations−$38.1MAgainst −$17.0M in Q1 FY2510-Q cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.
- Icu Medical ICUI public float $3.2B, Jun 30, 2025
- Dentsply Sirona XRAY public float $3.2B, Jun 30, 2025
- Inspire Medical Systems INSP public float $3.8B, Jun 30, 2025
- Masimo MASI public float $3.9B, Jun 28, 2025
- LivaNova LIVN public float $2.5B, Jun 30, 2025
